CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)

173.77 -4.84 (-2.71%)

As of 2026-03-03 12:05:53 EST

Charles River Laboratories International, Inc. is an American pharmaceutical and biotechnology contract research organisation (CRO) headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides preclinical and clinical laboratory services for the development of new drugs, vaccines, and medical devices. Its operations span at least 20 countries, offering research models, safety assessment, and manufacturing support services to pharmaceutical, biotechnology, and government clients.

Traded asNYSE: CRL
ISINUS1598641074
CIK0001100682
LEI549300BSQ0R4UZ5KX287
EIN061397316
SectorPharmaceuticals
IndustryServices-Commercial Physical & Biological Research
CEOJames C. Foster
Employees19,700
Fiscal Year End1227
Address251 BALLARDVALE ST, WILMINGTON, MA, 01887
Phone781-222-6000
Websitehttp://criver.com
Stock Quotes
trading_symbolregistrant_nametimepricechangepercentage_change
CRLCHARLES RIVER LABORATORIES INTERNATIONAL, INC.2026-03-03 12:05:53173.77-4.84-2.71
This is a preview of the latest data. Subscribe to access the full data.
Company Information
trading_symbolcentral_index_keyregistrant_nameisin_numberlei_numberein_numberexchangesic_codesic_descriptionfiscal_year_endstate_of_incorporationaddress_streetaddress_cityaddress_stateaddress_zip_codeaddress_countryaddress_country_codephone_numbermailing_addressbusiness_addressformer_nameindustryfounding_datechief_executive_officernumber_of_employeeswebsitemarket_capshares_issuedshares_outstandingdescriptionupdate_time
CRL0001100682CHARLES RIVER LABORATORIES INTERNATIONAL, INC.US1598641074549300BSQ0R4UZ5KX287061397316NYSE8731Services-Commercial Physical & Biological Research1227—251 BALLARDVALE STWILMINGTONMA01887UNITED STATESUS781-222-6000251 BALLARDVALE ST, WILMINGTON, MA, 01887251 BALLARDVALE ST, WILMINGTON, MA, 01887CHARLES RIVER LABORATORIES INTERNATIONAL INCPharmaceuticals1947James C. Foster19,700http://criver.com7,322,905,71149,217,00049,227,800Charles River Laboratories International, Inc. is an American pharmaceutical and biotechnology contract research organisation (CRO) headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides preclinical and clinical laboratory services for the development of new drugs, vaccines, and medical devices. Its operations span at least 20 countries, offering research models, safety assessment, and manufacturing support services to pharmaceutical, biotechnology, and government clients.2026-02-26 16:17:01
This is a preview of the latest data. Subscribe to access the full data.
CRL Stock Price (End-of-Day)
This is a preview of the latest data. Subscribe to access the full data.
CRL Stock Price (1-Minute)
This is a preview of the latest data. Subscribe to access the full data.
Market Cap
Fiscal YearMarket CapChange In Market CapPercentage Change In Market CapShares OutstandingChange In Shares OutstandingPercentage Change In Shares Outstanding
20257,322,905,711-3,240,678,894-30.677849,227,800-1,913,807-3.7422
202410,563,584,605-123,151,673-1.152451,141,607-208,163-0.4054
202310,686,736,278-705,720,955-6.194651,349,770364,2430.7144
This is a preview of the latest data. Subscribe to access the full data.
Executive Compensation
Executive NameExecutive PositionFiscal YearSalaryBonusStock AwardsIncentive Plan CompensationOther CompensationTotal Compensation
William D. BarboExecutive Vice President2023568,14401,522,274329,977105,9452,908,735
Birgit GirshickChief Operating Officer, Executive Vice President2023704,81102,964,471442,830132,8824,989,672
James C. FosterChair, Chief Executive Officer, President, Director20231,461,86609,138,7241,130,07471,88714,096,924
Flavia H. PeaseChief Financial Officer, Executive Vice President2023621,915600,0001,722,601324,223109,8673,811,326
Joseph LaplumeExecutive Vice President2023539,00001,702,429291,81097,5473,058,456
This is a preview of the latest data. Subscribe to access the full data.
Employee Count
Fiscal YearEmployee Count
202519,700
202420,100
202321,800
This is a preview of the latest data. Subscribe to access the full data.
Income Statements
Fiscal Year202520242023
Revenue4,015,382,0004,049,989,0004,129,409,000
Cost Of Revenue2,314,760,0002,345,781,0002,295,983,000
Gross Profit———
Research And Development Expenses———
General And Administrative Expenses743,073,000751,003,000747,855,000
Operating Expenses———
Operating Income25,162,000227,347,000617,261,000
Net Income-144,338,00022,203,000474,624,000
Earnings Per Share Basic-2.910.29.27
Earnings Per Share Diluted-2.910.29.22
Weighted Average Shares Outstanding Basic49,564,00051,380,00051,227,000
Weighted Average Shares Outstanding Diluted49,564,00051,628,00051,451,000
This is a preview of the latest data. Subscribe to access the full data.
Balance Sheet Statements
Fiscal Year202520242023
Cash And Cash Equivalents213,770,000194,606,000276,771,000
Marketable Securities Current———
Accounts Receivable708,856,000720,915,000780,375,000
Inventories299,103,000278,544,000380,259,000
Non Trade Receivables———
Other Assets Current96,108,000103,210,00087,879,000
Total Assets Current1,447,049,0001,403,071,0001,608,662,000
Marketable Securities Non Current———
Property Plant And Equipment1,655,219,0001,604,014,0001,639,741,000
Other Assets Non Current293,185,000278,233,000309,383,000
Total Assets Non Current1,655,219,0001,604,014,0001,639,741,000
Total Assets7,135,422,0007,528,345,0008,195,001,000
Accounts Payable148,800,000140,337,000168,937,000
Deferred Revenue210,418,000248,322,000241,820,000
Short Term Debt166,000155,0003,172,000
Other Liabilities Current222,158,000194,014,000203,210,000
Total Liabilities Current1,120,315,000994,101,0001,055,082,000
Long Term Debt2,136,360,0002,240,205,0002,647,147,000
Other Liabilities Non Current138,302,000195,212,000223,191,000
Total Liabilities Non Current2,803,913,0003,026,166,0003,480,921,000
Total Liabilities3,924,228,0004,020,267,0004,536,003,000
Common Stock492,000511,000513,000
Retained Earnings1,388,620,0001,812,100,0001,887,218,000
Accumulated Other Comprehensive Income-171,783,000-317,345,000-196,427,000
Total Shareholders Equity3,164,630,0003,461,503,0003,596,882,000
This is a preview of the latest data. Subscribe to access the full data.
Cash Flow Statements
Fiscal Year202520242023
Depreciation And Amortization403,312,000361,741,000314,124,000
Share Based Compensation Expense71,083,00069,891,00072,048,000
Other Non Cash Income Expense-2,504,000-33,251,000-1,592,000
Change In Accounts Receivable-35,737,000-21,612,00033,434,000
Change In Inventories48,777,000-16,804,00062,301,000
Change In Non Trade Receivables———
Change In Other Assets———
Change In Accounts Payable2,869,000-14,271,000-20,427,000
Change In Other Liabilities31,569,00051,995,000-38,642,000
Cash From Operating Activities737,646,000734,577,000683,898,000
Purchases Of Marketable Securities20,076,00052,876,00054,215,000
Sales Of Marketable Securities9,102,00041,687,0006,667,000
Acquisition Of Property Plant And Equipment219,152,000232,967,000318,528,000
Acquisition Of Business05,479,000194,785,000
Other Investing Activities-3,364,000-4,549,0002,294,000
Cash From Investing Activities-209,321,000-245,086,000-563,155,000
Tax Withholding For Share Based Compensation———
Payments Of Dividends———
Issuance Of Common Stock———
Repurchase Of Common Stock360,673,000119,175,00024,155,000
Issuance Of Long Term Debt1,227,534,0001,081,581,000776,353,000
Repayment Of Long Term Debt1,349,317,0001,493,769,000851,676,000
Other Financing Activities-14,022,000-31,442,000-4,145,000
Cash From Financing Activities-536,726,000-550,927,000-85,521,000
Change In Cash10,427,000-78,910,00043,266,000
Cash At End Of Period213,770,000194,606,000276,771,000
Income Taxes Paid119,644,000126,062,00090,374,000
Interest Paid101,718,000123,452,000132,101,000
This is a preview of the latest data. Subscribe to access the full data.
Key Metrics
Fiscal Year202520242023
Earnings Per Share-2.910.29.27
Price To Earnings Ratio-69.9863930.825.5016
Earnings Growth Rate-1,555-97.8425-3.1348
Price Earnings To Growth Ratio0.045-9.5132-8.135
Book Value Per Share64.788868.277171.4271
Price To Book Ratio3.14342.72653.3097
Ebitda485,647,000636,294,0001,015,832,000
Enterprise Value12,016,960,24011,610,654,80014,483,610,800
Dividend Yield———
Dividend Payout Ratio———
Debt To Equity Ratio0.67510.64720.7368
Capital Expenditures454,517,000326,014,000488,210,000
Free Cash Flow283,129,000408,563,000195,688,000
Return On Equity-0.04560.00640.132
One Year Beta1.34621.46471.3131
Three Year Beta1.36011.25471.1873
Five Year Beta1.25461.17581.1706
This is a preview of the latest data. Subscribe to access the full data.
Insider Transactions
Insider NameRelationship To IssuerTransaction DateAmount Of SecuritiesAcquired Or DisposedSecurities Owned Following Transaction
FOSTER JAMES CDirector, Chairman, President and CEO2026-01-3039,031A268,341
FOSTER JAMES CDirector, Chairman, President and CEO2026-01-3014,664D253,677
Parisotto Shannon MCEVP, Disc & Safety Assessment2026-01-304,236A16,251
Parisotto Shannon MCEVP, Disc & Safety Assessment2026-01-301,067D15,184
Mintz MarkEVP, Chief Information Officer2026-01-301,797A8,147
This is a preview of the latest data. Subscribe to access the full data.
House Trading
Name Of Reporting PersonReport DateStateTransaction TypeTransaction DateOwner TypeAmount
Jefferson Shreve2025-06-22IN06Purchase2025-05-08—$15,001 - $50,000
Jefferson Shreve2025-06-22IN06Sale2025-05-12—$15,001 - $50,000
Rob Bresnahan2025-05-31PA08Sale2025-05-15—$1,001 - $15,000
Rob Bresnahan2025-05-08PA08Purchase2025-04-08—$15,001 - $50,000
Julie Johnson2025-02-12TX32Purchase2025-01-15Joint$1,001 - $15,000
This is a preview of the latest data. Subscribe to access the full data.
Institutional Holdings
Investor NamePeriod Of ReportMarket ValueAmount Of SecuritiesPrice Per Security
MARSHALL WACE, LLP2025-12-3124,774,019124,193199.48
MANUFACTURERS LIFE INSURANCE COMPANY, THE2025-12-317,386,14637,027199.48
JOHNSON INVESTMENT COUNSEL INC2025-12-314,495,28222,535199.48
Kestra Advisory Services, LLC2025-12-31108,717545199.4807
Transamerica Financial Advisors, LLC2025-12-313,59118199.5
This is a preview of the latest data. Subscribe to access the full data.
Mutual Fund Holdings
Registrant NamePeriod Of ReportFund NameFund SymbolAmount Of UnitsValue In UsdPercentage Value Compared To Assets
VANGUARD TAX-MANAGED FUNDS2025-12-31Institutional SharesVTCIX59,49711,868,461.560.0437
VANGUARD TAX-MANAGED FUNDS2025-12-31Admiral SharesVTCLX59,49711,868,461.560.0437
VANGUARD INDEX FUNDS2025-12-31Institutional Plus SharesVSCPX1,116,962222,811,579.760.1369
VANGUARD INDEX FUNDS2025-12-31ETF SharesVB1,116,962222,811,579.760.1369
VANGUARD INDEX FUNDS2025-12-31Institutional SharesVSCIX1,116,962222,811,579.760.1369
This is a preview of the latest data. Subscribe to access the full data.